InvestorsHub Logo
Followers 829
Posts 119609
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Wednesday, 01/10/2018 12:42:37 PM

Wednesday, January 10, 2018 12:42:37 PM

Post# of 68
SNDX, Roche ink clinical collaboration for Entinostat + Tecentriq in second-line HR+/HER2- metastatic breast cancer:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-announces-clinical-collaboration-to-evaluate-entinostat-in-combination-with-anti-pd-l1-cancer-immunotherapy-in-breast-cancer-300580481.html

Roche will conduct the phase-1/2 trial; financial terms are not disclosed.

SNDX and Roche have a pre-existing collaboration (inked in 2015) to test Entinostat + Tecentriq in TNBC in a phase-2 trial called ENCORE 602.

In mid 2017, SNDX reported preliminary phase-2 data for Entinostat + Keytruda in first/second-line NSCLC (#msg-131432287).

SNDX has a second I-O agent, SNDX-6352, which is being tested in a collaboration with the NIH (#msg-127251680).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNDX News